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Frequent induction of chromosomal
aberrations in in vivo skin fibroblasts after
allogeneic stem cell transplantation: hints
to chromosomal instability after irradiation
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Abstract
Background: Total body irradiation (TBI) has been part of standard conditioning regimens before allogeneic stem
cell transplantation for many years. Its effect on normal tissue in these patients has not been studied extensively.
Method: We studied the in vivo cytogenetic effects of TBI and high-dose chemotherapy on skin fibroblasts from 35
allogeneic stem cell transplantation (SCT) patients. Biopsies were obtained prospectively (n = 18 patients) before, 3
and 12 months after allogeneic SCT and retrospectively (n = 17 patients) 23–65 months after SCT for G-banded
chromosome analysis.
Results: Chromosomal aberrations were detected in 2/18 patients (11 %) before allogeneic SCT, in 12/13 patients
(92 %) after 3 months, in all patients after 12 months and in all patients in the retrospective group after allogeneic
SCT. The percentage of aberrant cells was significantly higher at all times after allogeneic SCT compared to baseline
analysis. Reciprocal translocations were the most common aberrations, but all other types of stable, structural
chromosomal aberrations were also observed. Clonal aberrations were observed, but only in three cases they were
detected in independently cultured flasks. A tendency to non-random clustering throughout the genome was
observed. The percentage of aberrant cells was not different between patients with and without secondary
malignancies in this study group.
Conclusion: High-dose chemotherapy and TBI leads to severe chromosomal damage in skin fibroblasts of patients
after SCT. Our long-term data suggest that this damage increases with time, possibly due to in vivo radiation-
induced chromosomal instability.
Keywords: Chromosomal aberrations, Skin fibroblasts, Allogeneic stem cell transplantation, Total body irradiation,
Radiation-induced chromosomal instability, Secondary malignancies
Introduction
The most worrisome long-term side effect after success-
ful allogeneic SCT (SCT) is the increased risk of second-
ary malignancies.
These tumors develop several years after transplant-
ation with rising incidence over time. Besides younger
age at transplantation and chronic immunosuppression
through chronic graft-versus-host disease (GvHD), in-
tensive conditioning treatment with total body irradi-
ation (TBI) and high-dose chemotherapy has emerged as
a prominent risk factor after allogeneic SCT [1–7].
Ionizing radiation has the capacity to induce chromo-
somal aberrations in a variety of human tissues. Specific
chromosomal aberrations in blood cells like losses at
chromosomes 5 and 7, inv(16)(p13q22) and aberrations
involving 11q23, 17q21, or 21q22 have been identified in
chemotherapy-related myelodysplastic syndromes or
acute myeloid leukemias after chemotherapy as well as
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after radioiodine therapy for malignant or benign thyroid
disease [8–11]. Less cytogenetic data in secondary solid
tumors after radiotherapy are available, showing a di-
verse spectrum from simple balanced translocations to
complex aberrant karyotypes in few cases [12]. Sublethal
genomic damage may induce repairing cellular mecha-
nisms after various times of cell cycle arrest or propaga-
tion of genetic lesions, which could ultimately lead to
malignant transformation [13]. Evidence has accumu-
lated that DNA-damage not only occurs in directly irra-
diated cells, but also in the progeny of the irradiated
cells at delayed times after radiation exposure [13, 14].
Chromosomal aberrations have been described in cul-
tured skin fibroblasts after accidental irradiation in sin-
gle patients [15, 16] and in a few patients having
received radiotherapy [17–19]. No systemic in vivo cyto-
genetic analysis of irradiated skin fibroblasts has been
performed in patients.
We investigated the development of cytogenetic aber-
rations in skin fibroblasts from hematologic patients
after conditioning with high-dose chemotherapy and
fractionated TBI for allogeneic SCT. A prospective pa-
tient cohort was studied before and after allogeneic SCT
by taking sequential skin biopsies for chromosomal ana-
lysis. Another group of patients, who had received the
identical standard high-dose conditioning therapy before
allogeneic SCT was studied retrospectively. To our
knowledge, this is the first larger prospective as well as
retrospective study with a long-term follow-up on
in vivo induction of cytogenetic aberrations after
irradiation.
Patients and methods
Patients
Forty-six allogeneic stem cell transplant patients were
included in the study. Final analysis comprised 35 of
these 46 patients, because 11 of 46 patients were ex-
cluded from further analysis for the following reasons:
no total body irradiation as part of the conditioning
protocol before allogeneic SCT (n = 2), equivocal alloca-
tion of probes (n = 2), insufficient growth of fibroblasts
(n = 3), metaphases not evaluable after preparation
(n = 2), early death before 3 months after allogeneic
SCT (n = 2).
The prospective study group consisted of 18/35 pa-
tients. Skin biopsies were taken at three time points: im-
mediately before high-dose conditioning, 3 months and
12 months after allogeneic SCT.
The retrospective study group comprised 17/35 pa-
tients. Skin biopsies were obtained once from each pa-
tient, in median 38 months after SCT (range 23 to
65 months) (Table 1). The study was approved by the
local ethical committee of the Charité Universitätsmedi-
zin Berlin. All patients gave written informed consent.
Conditioning regimen
All patients underwent standard high-dose conditioning
with fractionated TBI with 6x2 gray (Gy) on three con-
secutive days and high-dose cyclophosphamide and / or
etoposide [20]. Three patients in the prospective group
were treated with antithymocyte globulin (ATG, Frese-
nius, Germany) (3x20 mg/kg) before SCT because of an
increased risk of graft failure due to a single HLA-
mismatch.
One patient with MDS received additional local radio-
therapy to thoracic skin areas and spleen because of
biopsy-proven skin infiltrates and enormous splenomegaly.
GvHD prophylaxis
Patients with a related donor received cyclosporine A
(CSA) for approximately 6 months plus short-course
methotrexate (MTX) i.v. or prednisone. In patients with
unrelated or mismatch donors, GvHD prophylaxis con-
sisted of CSA, MTX and prednisone. Prednisone was ta-
pered off after day 28.
Table 1 Patients’ characteristics in the prospective and the
retrospective study group
Prospective
group
Retrospective
group
Patients n 18 17
year of transplantation 1999-2001 1995-1999
Age at study entrymedian
(range)
37 years (16–49) 40 years (22–59)
Sex
male 12 8
female 6 9
Diagnosis
chronic myeloid leukemia 7 9
acute lymphoblastic leukemia 4 4
acute myelogenous leukemia 3 2
myelodysplastic syndrome 2 2
chronic myelomonocytic
leukemia
1 0
osteomyelofibrosis 1 0
Donor type n = 17*
related 9 13
unrelated 8 4
HLA-match
HLA-identical 15 16
HLA-1-mismatch 2 1
Stem cell source
bone marrow 3 16
peripheral blood 14 1
Legend to Table 1: *One patient did not proceed to transplantation due to
rapidly progressing disease at admission and was therefore only considered
for the cytogenetic analysis before SCT
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Processing of skin biopsies
After local anesthesia with lidocaine (1 %), skin samples
were obtained as 4 mm punch biopsies. Most biopsies
were taken from the upper back. Skin samples were cut
into small pieces and placed at the bottom of two cul-
ture flasks.
Fibroblast cultures
Fibroblasts were cultured in fetal calf serum and incu-
bated at 37 °C with 5 % CO2-pressure according to
standard techniques [21]. Culture medium was changed
weekly and cultures were checked regularly for typical
fibroblast growth. When sufficient fibroblasts were
grown, they were washed, trypsinized and passed to two
larger flasks to induce a synchronous cell division. As fi-
broblasts divide every 16–28 hours in culture, cells were
harvested after another 2–3 days, when they changed
from a spindle-shaped to a spheroidal form indicating
mitosis [22].
Chromosomal preparation
Colcemide was used to arrest cells in metaphase. After
trypsinization, cells were centrifuged and resuspended.
Warmed hypotonic solution was slowly added on a
shaker and cells were incubated for 20 minutes and then
fixed and incubated for another 10 minutes. At least five
rounds of fixation, incubation, centrifugation and resus-
pension were repeated before cells were applied onto an
object plate and dried.
Staining of metaphases
Banding was carried out using Trypsin-Giemsa-banding
technique [23]. Plates were incubated for 1 hour at 80 °C.
In a first step, object plates were incubated at 20 °C with
trypsin and isotonic PBS (phosphate-buffered saline).
After rinsing, they were then incubated for 4 minutes in
Giemsa staining solution, dried and covered.
Cytogenetic analysis
For each skin sample, 30 metaphases representing 30
cells in vitro were analyzed from the prepared slides.
Whenever cells from two separate culture flasks were
available, 15 metaphases were analyzed from each flask.
Karyotypes were defined according to the International
System for Human Cytogenetic Nomenclature [24]. For
each skin sample, the percentage of aberrant cells and
the mean number of breakpoints per aberrant cell were
determined from the 30 selected metaphases. If identical
aberrations were detected in two or more metaphases,
they were regarded as clonal as defined by others [17, 25].
We separately registered identical aberrations in only one
or in both of the flasks set up from one biopsy.
Statistics
Results of the descriptive analysis are given in median
and range.
In order to compare the frequencies of patients with
aberrant cells, McNemar-Test was used within the pro-
spective study group.
In order to compare the results of different time
points within the prospective study group including the
number of aberrant metaphases per 30 metaphases (= the
percentage of aberrant cells) and the mean number of
breakpoints per aberrant metaphase, a non-parametric fac-
torial analysis for repeated measurements and Wilcoxon
rank sum test for paired data were used. To compare differ-
ent clinical subgroups, Mann–Whitney U Test was per-
formed. Data were analyzed using statistical software (SPSS,
version 11.0; SAS, version 8.2). Significance was always
assessed at the p < 0.05 level, two-sided.
Results
Metaphase analysis
In the prospective group, chromosomal aberrations were
observed in only two out of 18 patients before SCT. The
percentage of aberrant cells was rather low in these two
patients and only one clone with a single reciprocal
translocation was found, namely t(12;18) in one and
t(5;17) in the other patient. One of these patients had re-
ceived prophylactic cranial irradiation prior to SCT
(24 Gy) due to ALL.
Three months after SCT, 12 out of 13 patients had ab-
errant cells in cytogenetic fibroblast analysis, and
12 months after SCT, all patients displayed cytogenetic
aberrations. The number of patients with aberrant cells
was significantly higher after SCT at both time points
compared to the number of affected patients before SCT
(Table 2).
All 17 patients (100 %) in the retrospective group had
an aberrant karyotype.
77 % of cells were aberrant three months and 63 % in
median 12 months after SCT. Difference between 3 and
12 months after SCT was not significant (p = 0.237, Wil-
coxon test), but difference between pre-SCT analysis and
both time points after SCT was highly significant.
In the retrospective group, a median of 83 % of the an-
alyzed cells was aberrant (Table 2).
The mean number of breakpoints per aberrant cell
was too small to allow statistical testing (Table 2).
82 - 94 % of the chromosomal aberrations observed in
the prospective and retrospective group were detected in
2 or more cells from one sample and were thus defined
as clonal. Most of them were found in only one of the
two flasks, however. The frequency of clonal aberrations
was not different between the single time points (data
not shown). In three patients, we detected cells with
identical cytogenetic aberrations in cultures from
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independently set up pieces of the same biopsy (i.e. in
two separately cultured flasks). Karyotype evolution
could be observed in 13 patients in our study: in
addition to the original aberration(s) defining a clone as
such, some cells had acquired further cytogenetic
aberrations.
Types of chromosomal aberrations
Only stable, structural chromosomal aberrations were
detected. Reciprocal translocations were the most com-
mon aberrations, but deletions, additional material of
unknown origin, inversions, insertions, derivative and
marker chromosomes were also observed. Unstable or
numerical aberrations were not seen (Fig. 1). Complex
aberrations as defined [26] were identified in five out of
13 patients 3 months after SCT, 2/11 at 12 months after
SCT and 8/17 in the retrospective group. Apart from
several three-break-translocations, we observed one
four-break- translocation (the latter in the retrospective
study group).
Breakpoint analysis
Chromosomal breakpoints affected all chromosomes in
both groups (except for chromosome Y in the retro-
spective group) and are illustrated in idiograms (Figs. 2
and 3). Figure 2 shows the breakpoints for the three time
points in the prospective group. In Fig. 3, breakpoints of
the retrospective group are displayed. Breakpoints ob-
served in clonal aberrations were only counted once for
each clone.
There was a tendency to a clustering at a number of
chromosome bands. We defined a cluster as a chromo-
somal band, where at least five breaks were detected
(coming from at least 3 different patients) [27]. 15 clus-
ters were detected in the prospective study group and 11
in the retrospective group. In Table 3, the observed and
expected percentages of breakpoints for the different
chromosomes are shown for the different time points.
The expected percentages were calculated assuming that
the distribution of breakpoints is proportional to phys-
ical length of chromosomes [28].
A higher rate of breakpoints than expected was ob-
served at chromosome arms 1p,1q and 14q (Table 3) [28].
Clinical parameters and correlation with cytogenetic
aberrations
The following clinical parameters were correlated with
the percentage of aberrant cells and the mean number of
breakpoints detected: patients’ sex, underlying disease,
donor type, GvHD of the skin and secondary tumors.
3 months after SCT, the percentage of aberrant cells
was significantly higher in patients with acute leukemias
compared to patients with other diagnoses (p = 0.028).
In the retrospective group as well, patients with acute
leukemias had a higher mean number of breakpoints per
aberrant cell as opposed to patients with other diagnoses
(p = 0.027, Mann–Whitney U test). All other analyses
did not reach statistical significance.
Secondary malignancies and correlation with cytogenetic
aberrations
With an updated follow-up of up to 14 years in the pro-
spective and 18 years in the retrospective group, second-
ary malignancies affected 7 out of 35 patients, 2 in the
prospective and 5 in the retrospective group. Secondary
malignancies developed 34 to 158 months (137 months
in median) after allogeneic SCT. Two patients had
malignant melanoma, another 2 patients had oral squa-
mous cell cancer, 1 patient had uterine cervical cancer, 1
patient had cholangiocellular carcinoma and 1 patient
developed bladder cancer. All patients had surgical re-
section of their secondary malignancies, 1 patient died
due to progressive relapse of bladder cancer 3 months
after tumor diagnosis, the others survived. Follow-up in
the seven patients was 22 months in median after diag-
nosis of secondary malignancy (3–61 months). Another
4 patients had basal cell cancer of the skin 94 to
120 months after allogeneic SCT, which were success-
fully removed by surgery.
Table 2 Cytogenetic fibroblast analysis in the prospective and the retrospective study group
Study group Prospective Retrospective
before SCT
(0 mo)
3 months after SCT p-value (0 vs 3 mo) 12 months after SCT p-value (0 vs 12 mo)
pat., n 18 13 11 17
pat. with aberrant metaphases,
n (%)
2 (11 %) 12 (92 %) 0.002 (McNemar) 11 (100 %) 0.002 (McNemar) 17 (100 %)
aberrant metaphases/30
metaphases (%)1
13 %; 27 %2 77 % (0-100 %) 0.002 (Wilcoxon) 63 % (33-97 %) 0.003 (Wilcoxon) 83 % (33-100 %)
mean no. of breakpoints/
aberrant metaphase1
2.3; 22 3.5 (2.3-6.8) NA 2.9 (1.6-5.8) NA 3.8 (1.8-5.4)
Legend to Table 2: pat. = patients. no. = number. 1 Results are given in median and range. 2 Because only two patients had cytogenetic aberrations before SCT,
median and range could not be given and only numbers of these two patients are shown. NA = not applicable because of small number of statistical events
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Fig. 1 Percentage of different structural chromosomal aberrations in skin fibroblasts. Legend to Fig. 1: chrom. = chromosomes
Fig. 2 Overview idiogram showing the distribution of all breakpoints in the prospective study group. Legend to Fig. 2: x: breakpoint from a
translocation; • breakpoint from an aberration other than a translocation; black: breakpoints before SCT; red: breakpoints 3 months after SCT;
green: breakpoints 12 months after SCT
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The percentage of aberrant cells in the retrospective
group was not different between the five patients with
secondary malignancies (80 % in median, range 67-93 %)
and the ten patients without secondary malignancy
(83 % in median, range 53-94 %).
Discussion
We herein describe the time-dependent development of
cytogenetic damage induced in skin fibroblasts after con-
ditioning with high-dose chemotherapy and TBI and
allogeneic SCT in a larger cohort of patients with a long
term follow-up.
The percentage of cells with an aberrant karyotype in
our study was significantly higher at all time points after
high-dose conditioning compared to the biopsies taken
before conditioning. Genetic damage occurred early, be-
cause most metaphases from biopsies taken 3 months
after SCT already presented an aberrant karyotype.
It is unlikely, that all these aberrations developed
ex vivo in culture, because most skin metaphases were
normal before SCT. In the literature there is only one
small series of four pediatric patients after TBI or total
lymphoid irradiation, where authors found 49 to 88 %
aberrant metaphases in the skin biopsies taken within
radiotherapy fields [19]. A few case reports have also
been published describing chromosomal aberrations in
skin fibroblasts after in vivo radiation exposure [15–18,
25], but without comparison to pre-radiation meta-
phases. To our knowledge, our study is the largest
in vivo cytogenetic study in irradiated patients with
hematologic malignancies, which follows chromosomal
aberrations over time.
Patients with acute leukemias, who had received more
intensive chemotherapy before TBI had a higher level of
cytogenetic damage. Therefore it cannot be excluded
that the extent of the observed cytogenetic damage in
the present study may have been influenced in part by
radiation enhancing effects of chemotherapy. However
in a small series of SCT-patients, abnormal karyotypes
were only observed in those with TBI, but not in those
without [19].
We mainly detected clonal aberrations in our study.
Most of them were only seen in single culture flasks, so
that in vitro clone formation cannot be excluded. A
Fig. 3 Overview idiogram showing the distribution of all breakpoints in the retrospective study group. Legend to Fig. 3: x: breakpoint from a
translocation; • breakpoint from an aberration other than a translocation
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Table 3 Number of different breakpoints and physical length of chromosomes
Chromosome/
chromosome arm
Physical
length (Mb)
Prospective group Retrospective group
before SCT after 3 months after 12 months
1p 128 1 10 5 23
1q 135 1 3 23 16
1 263 (8,0 %) 3 13 (5,8 %) 30 (12,7 %) 39 (10,3 %)
2p 99 - 10 5 12
2q 156 - 12 9 15
2 255 (7,7 %) - 22 (9,9 %) 14 (5,9 %) 27 (7,1 %)
3p 99 - 9 9 10
3q 115 - 10 9 14
3 214 (6,5 %) - 19 (8,5 %) 19 (8,1 %) 24 (6,3 %)
4p 56 - - 7 4
4q 147 - 7 5 15
4 203 (6,2 %) - 7 (3,1 %) 12 (5,1 %) 21 (5,5 %)
5p 52 - 1 5 4
5q 142 1 12 3 15
5 194 (5,9 %) 1 13 (5,8 %) 9 (3,8 %) 21 (5,5 %)
6p 65 - 6 6 14
6q 118 - 9 6 6
6 183 (5,6 %) - 15 (6,7 %) 12 (5,1 %) 21 (5,5 %)
7p 65 - 9 4 5
7q 106 - 9 5 10
7 171 (5,2 %) - 18 (8,1 %) 9 (3,8 %) 15 (4,0 %)
8p 50 - 3 1 8
8q 105 - 4 4 13
8 155 (4,7 %) - 7 (3,1 %) 5 (3,4 %) 21 (5,5 %)
9p 51 - 6 2 3
9q 94 - 5 4 15
9 145 (4,4 %) - 11 (4,9 %) 6 (2,6 %) 18 (4.7 %)
10p 44 - 2 6 5
10q 100 - 6 6 15
10 144 (4,4 %) - 9 (4,0 %) 12 (5,1 %) 22 (5,8 %)
11p 58 - 5 3 2
11q 86 - 5 7 6
11 144 (4,4 %) - 10 (4,5 %) 10 (4,2 %) 9 (2,4 %)
12p 39 - 4 2 3
12q 104 1 4 5 6
12 143 (4,3 %) 1 8 (3,6 %) 7 (2,9 %) 9 (2,4 %)
13p 16 - - 1 3
13q 98 - 7 9 11
13 114 (3,5 %) - 8 (3,6 %) 11 (4,7 %) 14 (3,7 %)
14p 16 - 1 1 -
14q 93 1 9 13 20
14 109 (3,3 %) 1 11 (6,3 %) 14 (5,9 %) 22 (5,8 %)
15p 17 - 2 4 6
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stronger hint to in vivo clonality could be found in three
of our patients with identical aberrations in cultures
from independently set up pieces of the same biopsy.
Hints to in vivo clone formation come from case reports
by others as well [15, 17–19]. The strongest evidence for
in vivo clone formation was reported by Mouthuy and
Dutrillaux, who found cells with identical aberrations in
two skin biopsies, which were taken with a time interval
of one year [15]. This is a unique finding neither con-
firmed by us nor others.
A clone is not necessarily completely homogenous
since subclones may have evolved exhibiting additional
aberrations [24]. This phenomenon described as karyo-
type evolution was observed in 13 patients of our study.
Reciprocal translocations were the most common type
of aberration observed at all time points. In 16 of our
patients, complex aberrations were detected. The most
complex aberration was a four-break-translocation seen
in a patient of the retrospective group.
The high rates of aberrations in our study, karyo-
type evolution and the presence of complex aberra-
tions are in line with the concept of permanent
genomic instability through the cytotoxic effects of ir-
radiation [13, 14, 29].
Studies of in vitro irradiated fibroblasts have demon-
strated that the radiation-induced breakpoints are dis-
tributed non-randomly throughout the genome [27, 30,
31]. In our study some of the clusters were detected at
published breakpoints like, for example, 1p22. Both arms
of chromosome 1 have been affected frequently in
in vitro studies of irradiated diploid cells [27]. We are re-
served in the interpretation of the results of our
breakpoint analysis on the basis of this conventional
cytogenetic study. We see hints for a non-random
distribution of breakpoints in our study (Figs. 2 and 3,
Table 3).
Interestingly, several of the observed clusters were lo-
cated at bands, where genes for the chromosome in-
stability syndromes have been mapped to. Additionally, a
cluster was detected at 14q32, which is known to be a
preferential site of chromosomal breakage in ataxia-
telangiectasia patients [32]. The genes involved in the
chromosome instability syndromes like Ataxia telean-
giectasia or Fanconi anemia are critical in the early de-
tection of induced damage and subsequent induction of
cellular response to repair the damage [13, 33]. Patients
with these or other related disorders have a dramatically
increased malignancy risk [33]. An interesting task for
future studies would be to compare known gene loci
and breakpoints in these cancer-prone disorders with
radiation-induced aberrations with molecular tools. We
hypothesize, that a congruence of breakpoints induced by
radiation with chromosomal breakage sites in chromo-
some instability syndromes would support the concept of
radiation-induced instability through disturbances in
DNA repair as suggested by others [13].
Due to the limited number of patients in our experi-
mental study, the rates of secondary malignancies can-
not be compared with large register data [1–7],
although the 20 % cumulative incidence of secondary
malignancies seems rather high. As virtually all pa-
tients had cytogenetic aberrations in skin, additional
cellular mechanisms must be involved in carcinogen-
esis in these patients. It also seems very likely, that
Table 3 Number of different breakpoints and physical length of chromosomes (Continued)
15q 89 - 6 7 9
15 106 (3,2 %) - 9 (6,7 %) 11 (4,7 %) 15 (3,9 %)
16 98 (3,0 %) - 10 (4,5 %) 9 (3,8 %) 16 (4,2 %)
17 92 (2,8 %) 1 8 (3,6 %) 6 (2,6 %) 16 (4,2 %)
18 85 (2,6 %) 1 5 (2,2 %) 6 (2,6 %) 12 (3,2 %)
19 67 (2,0 %) - 6 (2,7 %) 4 (1,7 %) 6 (2,4 %)
20 72 (2,2 %) - 6 (2,7 %) 7 (3,0 %) 10 (2,6 %)
21 50 (1,5 %) 1 5 (2,3 %) 5 (2,1 %) 2 (0,5 %)
22 56 (1,7 %) 1 3 (1,4 %) 5 (2,1 %) 3 (0,8 %)
Xp 62 (1,9 %) - - 4 10
Xq 102 (3,1 %) - 1 6 10
X 164 (5,0 %) - 2 (0,9 %) 10 (4,3 %) 22 (5,8 %)
Y 59 (1,8 %) - 1 (0,5 %) 1 (0,4 %) -
Sum of breakpoints: 10 222 235 379
Legend to Table 3: Physical length of chromosome arms is given in Mb =Megabases according to [28]. Distribution of breakpoints is shown for chromosome arms
and for whole chromosomes. In a few cases (mainly due to derivative chromosomes), breakpoints could only be localized to a chromosome, but not to a certain
chromosome arm. Distribution of the breakpoints on the shorter chromosomes 16–22 and Y (chromosome groups E-G) is only shown for the whole chromosome
and not for chromosome arms
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organ-specific cellular changes are involved in organ
carcinogenesis.
More advanced technologies like FISH, SKY and mo-
lecular techniques have evolved rapidly with more data
being available on mechanisms of cell damage and repair
due to radiation injury [34–36]. These data, however, are
either from cell culture systems and mice models or did
not involve patients with TBI, while our data were from
in vivo irradiated patients’ fibroblasts. Experimental ap-
proaches and organ-specific analyses might detect spe-
cific cytogenetic and molecular aberrations, which would
increase our understanding of organ-specific radiation-
induced cellular injury and carcinogenesis.
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